Soleno Therapeutics Inc., of Redwood City, Calif., reported data from a pilot trial testing diazoxide choline controlled-release tablet (DCCR) in 13 patients with Prader-Willi syndrome at the 10th International Meeting of Pediatric Endocrinology in Washington.